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Abstract
Background: The role of natural killer (NK) cells in granulomatosis with polyangiitis (GPA) is poorly understood. We
recently reported that peripheral blood NK cell percentages correlate with the suppression of GPA activity (cohort I).
The purpose of the current study was to further characterize NK cell subsets, phenotype and function in a second
GPA cohort (cohort II).
Methods: Peripheral blood lymphocyte subsets were analyzed at a clinical diagnostic laboratory. Clinical data were
extracted from medical records and patients were grouped according to their activity state (remission vs. active/
non-remission). Separate analysis (cohort II, n = 22) and combined analysis (cohorts I and II, n = 34/57) of NK cell
counts/percentages was performed. NK cell subsets and phenotypes were analyzed by multicolor flow cytometry.
Cytotoxicity assays were performed using 51Cr-labeled K562 target cells.
Results: In cohort II, NK cell counts were lower than the lower limit of normal in active GPA, despite normal
percentages due to lymphopenia. NK cell counts, but not other lymphocyte counts, were significantly higher in
remission. Combined analysis of cohorts I and II confirmed decreased NK cell counts in active GPA and increased
percentages in long-term remission. Follow-up measurements of six patients revealed increasing NK cell
percentages during successful induction therapy. Multicolor analysis from cohort II revealed that in active GPA,
the CD56dim subset was responsible for decreased NK cell counts, expressed more frequently CD69,
downregulated the Fc-receptor CD16 and upregulated the adhesion molecule CD54, the chemokine receptor
CCR5 and the activating receptor NKG2C. In remission, these markers were unaltered or marginally altered. All
other receptors investigated (NKp30, NKp44, NKp46, NKG2D, DNAM1, 2B4, CRACC, 41BB) remained unchanged.
Natural cytotoxicity was not detectable in most patients with active GPA, but was restored in remission.
Conclusions: NK cell numbers correlate inversely with GPA activity. Reduced CD56dim NK cells in active GPA have
an activated phenotype, which intriguingly is associated with profound deficiency in cytotoxicity. These data
suggest a function for NK cells in the pathogenesis and/or modulation of inflammation in GPA. NK cell numbers,
phenotype (CD16, CD69, NKG2C) or overall natural cytotoxicity are promising candidates to serve as clinical
biomarkers to determine GPA activity.
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Background
Natural killer (NK) cells make up about 5–15 % of all
peripheral blood lymphocytes (PBL). They are tightly
regulated lymphocytes with cytotoxic activity against
stressed and/or antibody-coated cells [1–4]. Moreover,
NK cells link innate and adaptive immunity [1]. Adaptive
immunity can be modulated by NK cells at different
stages [5], e.g. by secretion of interleukin (IL)-10 [6] and
killing of other immune cells, such as activated CD4+ T-
cells [7]. Two major NK cell subsets are well-established:
CD56bright NK cells are dominant in secondary lymph-
atic tissues and presumably precursors of CD56dim NK
cells, which are mature cytotoxic cells and make up
>90 % of blood NK cells. CD56dim NK cells can be fur-
ther subdivided based on the expression of CD62L and
CD57 [2]. Important homeostatic factors are IL-15 and
IL-18 [8].
NK cell immune recognition and activity is balanced
by activating and inhibiting receptors [9], but can be
modulated on several levels [2]. CD56dim NK cells bear
the low affinity Fc-γ-receptor CD16 (FcγRIIIA). CD16
binds IgG1 and mediates antibody-dependent cellular
cytotoxicity (ADCC) [10]. CD16 plays a prominent role
in activating CD56dim NK cells [11]: CD16 activates rest-
ing NK cells by itself, whereas all other receptors need
co-activation. Following stimulation, CD16 is downregu-
lated [12] by means of shedding [13] and intracellular
uptake [14].
Granulomatosis with polyangiitis (GPA) is a systemic
inflammatory, prototype autoimmune disease character-
ized by the presence of anti-proteinase-3 autoantibodies.
Granulomas and vasculitis histologically define GPA.
Knowledge about the involvement of NK cells in GPA is
limited. We have recently discovered that blood NK cell
percentages correlate negatively with disease activity and
positively with the duration of remission [15]. NK cells
were not detectable in active granulomatous lesions [15].
To date, alterations in the phenotype or function of NK
cells have not been linked with disease activity.
Methods
Patient consent and ethical approval
Informed consent was obtained from the patients before
study initiation. The ethics committee of the University
of Heidelberg approved this study.
Patients and controls
Two GPA patient cohorts were analyzed. Details of co-
hort I have been published [15]; 28 different patients
were included. Blood was taken at different time points
from 4/28 patients, so that 35 measurements were per-
formed in total (NK cell percentages in PBL). Cohort II
consisted of 19 different patients, in total providing 22
PBL subset measurements and 19 analyses of phenotype.
Characteristics of patients in cohort II are specified in
Table 1. In both cohorts a total of 57 measurements
were analyzed. Multiple measurements of the same pa-
tients with GPA were included, as the activity state
might have been different (see below).
Analysis of lymphocyte subsets (cohort II)
Lymphocyte subsets in 22 samples from 19 different pa-
tients were analyzed on the same day of blood donation
in a clinical diagnostic laboratory using a standard anti-
body kit (clinical grade quality) from Beckman Coulter
(Brea, CA, USA). We did not perform this test with a
healthy control group, as upper and lower limits of nor-
mal are already established for clinical diagnostics (see
dotted lines in Fig. 1).
Definitions and analysis of medical records
Medical records from all patients from cohorts I and II
were (re-)analyzed. To best reflect clinical activity, the def-
initions of GPA activity states from current recommenda-
tions for clinical studies [16–19] were slightly adapted and
applied as follows: remission on drug - inactive disease,
absence of symptoms for at least 6 months, prednisone in-
take <10 mg/day; remission off drug - inactive disease, ab-
sence of symptoms, no disease-modifying antirheumatic
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drug (DMARD) intake for at least 6 months. By definition,
the Birmingham vasculitis activity score (BVAS) had to be
0 to identify remission; response was defined as BVAS re-
duction >50 % compared to the last clinical visit; refrac-
tory disease was defined as no response after 6 weeks of
treatment or progressive disease after 4 weeks of treat-
ment, or chronically persisting activity with one major or
three minor BVAS items; grumbling disease was defined
as minor, non-organ-threatening symptoms that usually
respond to elevation of prednisone doses or DMARDs
(e.g. arthralgia, myalgia or fever); major relapse was
defined as one major or three minor BVAS items; minor
relapse was defined as recurrent disease activity without
organ-threatening manifestations, and early relapse was
defined as relapse <6 months after initiation of induction
therapy.
The activity state and BVAS were determined at the
time of blood donation, i.e. the day of inclusion in the
study. To facilitate the analysis, on-drug and off-drug re-
mission were grouped into a single group classified as in
remission. All other activity states were termed active or
non-remission. Please note that in remission requires the
absence of symptoms (i.e. BVAS of 0) for at least 6 months,
therefore patients with a BVAS of 0 can principally be al-
located to the non-remission group. The definition for
short-term and long-term remission (< vs. >/= 4.08 years)
was adopted from the parental study [15]. Physician global
assessment was categorized as active, inactive or diverse;
the diverse category includes uncertainties and ambigu-
ities (e.g. increased use of prednisone by the patient be-
cause of unspecific arthralgia). Therapeutic consequence
was categorized as intensified, unchanged or reduced, ac-
cording to the physician’s decision about the use of im-
munosuppressive pharmaceutical treatment.
NK cell phenotyping/multicolor flow cytometry
Peripheral blood mononuclear cells (PBMCs) from patients
(cohort II; in remission, n = 11; active, n = 8; total, n = 19;)
and nine healthy controls (HC) were isolated by Ficoll-
Paque density gradient centrifugation using Pancoll
medium (PAN-Biotech GmbH, Aidenbach, Germany) and
deep-frozen the same day. Samples were thawed and
200,000 PBMCs were incubated for 20 minutes on ice in
Zombie aqua (Biolegend, San Diego, CA, USA) dissolved in
PBS, washed, incubated for 20–30 minutes on ice with a
cocktail of monoclonal antibodies (panels, see Additional
file 1: Methods), then washed and directly analyzed on a
four-laser flow cytometer (LSR Fortessa, BD Biosciences,
San Jose, CA, USA). Data were processed using FlowJo®
software (FlowJo LCC, Ashland, OR, USA). The following
mean counts of live CD56dimCD16pos. NK cells were
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Fig. 1 Natural killer (NK) cell counts are significantly lower in active (non-remission) granulomatosis with polyangiitis. Peripheral blood lymphocyte
counts and lymphocyte subsets were determined by flow cytometry (clinical grade quality), as indicated in the figure. Only patients from cohort II
were included (total patients = 22, patients with active disease = 10, patients in remission = 12). Boxplots show traditional Tukey whiskers; dotted
lines show upper and lower limits of normal. Statistical analysis was performed using the Mann-Whitney test; ns not significant; ***p = 0.0005
Table 1 Patient characteristics (cohort II and CD*)
Characteristic Value
Patients with GPA, n 22
Men/women, n 14/8
GPA in remission, n (%) 12/22 (55 %)
Age in years, median (range) 55.5 (35–79)
Duration of remission in years
(of inactive GPA), mean (range)
4.4 (1–20)
GPA non remission (active), n (%) 10/22 (45 %)
Age in years, median (range) 51.5 (33–64)
BVAS, mean (range) 4.5 (0–19)
Localized GPA (upper airways
and ENT organs only), n (%)
4/22 (18 %)
Generalized GPA, n (%) 18/22 (82 %)
ANCA
Positive 17/22 (77 %)
Negative 3/22 (14 %)
Not determinable 2/28 (9 %)
Patients with CD, n 12
Men/women, n 3/9
GPA granulomatosis with polyangiitis, BVAS Birmingham vasculitis activity
score, ENT ear, nose and throat, ANCA antineutrophil cytoplasmic antibody,
CD* inactive systemic inflammatory control diseases other than GPA
comprising systemic lupus erythematosus (n = 4), panarteriitis nodosa (n = 1),
overlap connective tissue disease (n = 1), chronic inflammatory bowel disease
(n = 1), CREST syndrome (n = 1), primary Sjögren’s syndrome (n = 1),
polymyalgia rheumatica (n = 1) and giant cell arteriitis (n = 2)
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analyzed (panel 2): 15,000 (HC); 8,000 (GPA in remission)
and 3,000 (GPA non-remission). The lowest counts of live
analyzed CD56dimCD16pos. NK cells were 307 and 446
within the GPA non-remission group; all others were
>1,500 per measurement.
Cytotoxicity assay
The target cell line K562 was grown in medium (IMDM,
10 % FCS, 1 % penicillin/streptomycin) to mid-log phase.
5 × 105 target cells were labeled in 100 μL assay medium
(IMDM with 10 % FCS and penicillin/streptomycin) with
100 μCi of 51Cr for 1–2 hours at 37 °C. Cells were washed
twice in assay medium and resuspended at 5 × 104 cells/mL
in assay medium. Five thousand target cells/well were used
in the assay. Effector cells (freshly isolated, thawed PBMCs)
were resuspended in assay medium and left untreated over-
night. PBMC viability was then analyzed using CASY® Cell
Counter (OMNI Life Science GmbH & Co. KG, Bremen,
Germany). PBMCs were mixed with labeled target cells in a
V-bottom 96-well plate. Maximum release was determined
by incubation in 1 % Triton X-100. For spontaneous re-
lease, target cells were incubated without effector cells in
assay medium alone. All samples were analyzed in tripli-
cates. Plates were incubated for 4 hours at 37 °C. Super-
natant was harvested, and 51Cr release was measured in a
gamma counter. Percentage of specific release was calcu-
lated as:
((Experimental release – Spontaneous release)/(Maximum
release – Spontaneous release)) × 100.
Statistical analysis
Exploratory statistical analysis was performed; p values have
to be interpreted descriptively. Normal distribution was not
assumed; non-parametric statistical tests were used. The
Kruskal-Wallis test and Dunn's post hoc test were used for
multiple comparisons; the Mann-Whitney test was used to
compare two patient groups; Spearman’s test was used to
test for correlation. The Wilcoxon signed rank test was used
to compare NK cell proportions from the same donors at
different time points. All tests were performed with a signifi-
cance level of 5 % (confidence interval 95 %).
Results
NK cell counts were significantly lower in active
(non-remission) GPA
Lymphocyte subsets in 22 samples from 19 different pa-
tients in cohort II were analyzed. Patients with GPA had
lymphopenia, irrespective of disease activity (Fig. 1). In ac-
tive GPA, lymphopenia resulted from collectively reduced
T, B and NK cells. Numbers of NK cells were markedly
low; a median of 33.5 NK cells/nl corresponded to 1/3 of
the lower limit of normal. On statistical analysis using the
Wilcoxon signed rank test, NK cell counts from non-
remission GPA were significantly lower than a hypothetic
value of 188.5 (the mean of the lower and upper threshold
of normal NK cell counts; p = 0.002). Interestingly, in re-
mission, NK, but not T or B cell counts, were in the nor-
mal range and were statistically significantly higher than
in active GPA.
NK cells were inversely correlated with GPA activity
Both NK cell lymphopenia in active GPA and the signifi-
cantly lower NK cell counts in active vs. inactive GPA were
confirmed in a combined analysis of cohort I (n= 12) and
cohort II (n = 22; total = 34) after subgrouping according to
either BVAS (>/= 0, p= 0.0152, not shown) or activity state
(Fig. 2a, left graph). Likewise, analysis of physician global as-
sessment and therapeutic consequence showed reduced NK
cell counts in active vs. inactive GPA (Fig. 2a, middle and
right graphs). The majority of patients with non-remission
GPA had NK cell counts lower than the clinically estab-
lished threshold of "normal". When comparing non-
remission GPA with inactive control disease (CD) (Fig. 2a),
the corresponding post hoc test was not significant, whereas
the direct comparison using the Mann-Whitney test was
significant, indicating borderline significance. The latter is
presumably due to the relatively low number of patients
with CD and the large range of scattered NK counts within
the CD group.
In the combined analysis, the total of 57 measure-
ments of blood lymphocyte percentages reproduced the
previous finding of increased NK cell percentages during
remission [15]. NK cell percentages in long-term remis-
sion were higher than usually seen in healthy individuals
(Fig. 2b, left graph, and [15]). Likewise, on analysis of
physician global assessment and therapeutic conse-
quence there were increased NK cell percentages in in-
active vs. active GPA (Fig. 2b, middle and right graphs).
These data indicate that NK cells increase during the
transition from active to inactive GPA. We assessed NK
cell percentages in six patients at least twice during the
course of induction therapy. In 5/6 patients, NK cell per-
centages increased during successful induction therapy
(Fig. 2c). In 1/6 patients, NK cell percentages were lower
in the last measurement. This patient had high initial
disease activity (BVAS 2006 = 23), suffered from early re-
lapse between the first and the last measurement (BVAS
2006 = 24), and finally responded to therapy with persist-
ent activity at the last measurement (BVAS 2006 = 12).
Absolute NK cell counts were determined in 4/6 pa-
tients, showing a minor increase in 3/4 patients (not
shown, not statistically significant). Furthermore, we
had the chance to observe patients who experienced
clinical deterioration during follow up; all four
patients had decreased NK cell percentages compared
to the previous value (not shown, not statistically
significant).
Merkt et al. Arthritis Research & Therapy  (2016) 18:204 Page 4 of 12
These data extend our previous study showing that
NK cell numbers are lower than normal in active GPA
and normalize during clinical amelioration. The finding
that NK cell percentages further increase during long-
term remission is confirmed (by additional patients from
cohort II and by the new analysis methods). NK cell per-
centages are likely to reflect disease activity within a
given patient.
CD56dim but not CD56bright NK cells were reduced in
active GPA
We established a set of multicolor flow cytometry panels
to investigate NK cell subsets and important surface
proteins. PBMCs from 18 different patients in cohort II
and 9 healthy controls (HC) were isolated by density
gradient centrifugation and frozen. Except for one pa-
tient, no double measurements were included (total = 19,
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Fig. 2 Natural killer (NK) cells inversely correlate with granulomatosis with polyangiitis (GPA) activity. Patients from cohort I and II were included;
cohort I has been published in a parent study [15]; cohort II is described in Table 1. a Absolute NK cell numbers are decreased in active GPA. Cohort I,
n = 12; cohort II, n = 22; total = 34; control disease (CD), n = 12 patients with inactive systemic inflammatory control diseases (see [15] and Table 1).
Dotted lines show upper and lower limits of normal NK cell numbers according to our clinical diagnostic laboratory; medians are indicated by bars. Left
subgrouping according to activity states showed significant differences among the groups (Kruskal-Wallis test, p = 0.0029); middle physician global
assessment (Kruskal-Wallis test, p= 0.0486); right therapeutic consequence (Kruskal-Wallis test, p= 0.0397). b NK cell percentages are increased in patients with
GPA in long-term remission. Cohort I, n= 35; cohort II, n= 22; total = 57; CD, n=12. Dotted lines correspond to the upper and lower limits of normal NK cell
percentages, according to our clinical diagnostic laboratory; medians are indicated by bars. Left subgrouping according to activity states showed
significant differences among the groups (Kruskal-Wallis test, p= 0.0001); middle physician global assessment (Kruskal-Wallis test, p= 0.0007); right therapeutic
consequence (Kruskal-Wallis test, p= 0.0108). a, b The threshold for long-term remission (4.08 years) had been determined in the parent study [15]. Dunn's
post hoc test was significant where indicated in the graphs. c NK cells increase during successful induction therapy. NK cell percentages from six patients with
GPA were determined at two or more time points during induction therapy (cohort I, four patients; cohort II, two patients). The first and last measurements
are depicted, respectively. Statistical analysis was performed using the Wilcoxon signed rank test, p= 0.0585
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remission = 11 and active = 8 patients). The age was not
significantly different between HC and patients in remis-
sion and non-remission (Additional file 2: Figure S3).
NK cells were defined as viable CD3-negative CD56-
positive lymphocytes.
We first focused on traditional NK cell subsets. As we
had not found differences in the distribution of CD56dim
and CD56bright NK cells in the parent study [15], we
used another, more sensitive anti-CD56 antibody
(Fig. 3a). We found that the percentages of CD56dim NK
cells among total NK cells were lower in active GPA,
whereas CD56bright NK cell percentages were increased
(Fig. 3b). On analysis of absolute numbers the CD56dim
NK cells were significantly lower in active GPA than in
remission, whereas the counts of CD56bright NK cells
were not significantly different (Fig. 3c). Therefore, a de-
crease in the CD56dim subset was responsible for the de-
creased total NK cell numbers in active GPA.
CD56dim NK cells in active GPA express high levels of
lymphocyte activation marker CD69 and low levels of
Fc-gamma receptor CD16
CD56dim(CD16 pos.) NK cells more frequently expressed
CD69 in active GPA (Fig. 4a, left graph). CD69 expression
was also slightly increased in remission (Dunn's post hoc
test not significant; Mann-Whitney test, p = 0.0122). On
the contrary, CD69 on CD56bright(CD16 neg.) NK cells
was not different between HC and patients with GPA
(Fig. 4a, right graph).
The activation of NK cells via CD16 leads to the
downregulation of surface CD16, according to previous
literature. Under healthy conditions, >90 % of
CD56dim(CD16 pos.) NK cells express CD16 in a
CD16bright fashion (Fig. 4b). In active GPA, the propor-
tions of CD16bright CD56dim(CD16 pos.) NK cells were
significantly lower (Fig. 4b). The means of CD16 fluores-
cence intensity were significantly lower in active GPA
than in remission (p = 0.0044, not shown). Together,
these data demonstrate that the numerically decreased
CD56dim NK cells are activated in active GPA. CD56bright
NK cells, which do not express CD16 [20], were not
activated. The following analysis therefore concentrates
on CD56dim NK cells.
The expression of numerous NK cell receptors was not
different in HC and GPA in remission or active GPA
CD56dim NK cells can be further subgrouped by the ex-
pression of the maturity markers CD62L and CD57.
CD62L was slightly increased and CD57 was slightly de-
creased on CD56dim NK cells in both GPA in remission
and active GPA (not shown, not statistically significant).
The expression of CD69 was not different between
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Fig. 3 CD56dim but not CD56bright natural killer (NK) cells are reduced in active (non-remission) granulomatosis with polyangiitis (GPA). Peripheral
blood mononuclear cells from patients with GPA (total = 19, in remission = 11 and non-remission = 8 patients) and 9 healthy controls (HC) were
isolated by density gradient centrifugation and analyzed by multicolor flow cytometry (panel III). a Gating strategy. Peripheral blood lymphocytes were
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by co-staining of CD3 (negative) and CD56 (positive). b Percentages of CD56dim (left) and CD56bright (right) NK cells among total NK cells were plotted
according to activity states. The Kruskal-Wallis test was significant in both graphs (p= 0.0084 and p= 0.0081), Dunn's post hoc test was significant where
indicated in the graphs; bars represent medians. c Absolute numbers of CD56dim (left) and CD56bright (right) NK cells were calculated on the basis of the
absolute NK cell counts shown in Fig. 1. The Mann-Whitney test was significant only for CD56dim NK cells (p= 0.0149); bars indicate medians. ns
not significant
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CD57 and CD62L-positive CD56dim(CD16 pos.) NK cells
(not shown). NKp30, NKp44, NK46, NKG2D and
DNAM1 did not differ between HC and patients with
GPA in remission or non-remission (Additional file 3:
Figure S1). In addition, 2B4, CRACC and 41BB were un-
altered (not shown).
NK cell phenotype in relation to immunosuppressive
treatment
Prednisone dosage was not significantly different between
patients in remission and non-remission (Additional file 4:
Figure S2A). There was no correlation between prednis-
one dosage and the proportion of CD16bright and CD69
pos. CD56dim(CD16 pos.) NK cells (Additional file 4:
Figure S2B).
Apart from prednisone, patients with GPA took diverse
immunosuppressive drugs (Additional file 4: Figure S2C).
We compared the proportion of CD16bright and CD69
pos. CD56dim (CD16 pos.) NK cells after subgrouping ac-
cording to immunosuppressive drugs (Additional file 4:
Figure S2D and E, left graphs). On statistical analysis using
the Kruskal-Wallis test, there was no statistical difference
between the patient groups. The Kruskal-Wallis test was
only positive after the inclusion of the HC group; the only
positive post hoc tests were comparisons between patients
who received azathioprine and HC. In the azathioprine
group, 4/ 6 patients were not in remission. Comparing pa-
tients receiving azathioprine and rituximab according to
their disease activity, we observed a clear tendency to-
wards phenotypic alterations that were more prominent in
patients with active GPA (Additional file 4: Figure S2D
and E, right graph).
Increased expression of adhesion molecule CD54
(ICAM-1), chemokine receptor CCR5 and NKG2C on
CD56dim NK cells in active GPA
CD54 was expressed on all CD56dim NK cells, which did
not differ between HC and patients with GPA (not
shown). However, the mean fluorescent intensity of
CD54 was significantly increased in active GPA (Fig. 5a).
CCR5 was not expressed, or was expressed at low
levels on CD56dim NK cells in HC, but the percentage of
CCR5 pos. CD56dim NK cells was significantly higher in
patients with active GPA than in HC (Fig. 5a). CXCR3
tended to be increased in active GPA but was not statis-
tically significant (Fig. 5a). NKG2C was expressed at low
levels (0–20 %) on HC CD56dim NK cells, but was sig-
nificantly increased in active GPA (Fig. 5b). NKG2C ex-
pression on CD56bright NK cells was not different
between HC and patients with GPA.
Next we investigated whether CD54, CCR5 and NKG2C
were co-expressed on CD56dim NK cells. CD54 and
CXCR3 were not higher on NKG2C-positive than on
NKG2C-negative CD56dim NK cells (Additional file 5:
Figure S4). Despite being significantly more frequently
expressed on NKG2C-positive cells, CCR5 was also found
on NKG2C-negative cells (Additional file 5: Figure S4).
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Therefore, these receptors were not increased on the same
cells. To summarize, the expression levels of CD54, CCR5
and NKG2C were independently increased on CD56dim
NK cells in active GPA.
Natural cytotoxicity was significantly decreased in active
GPA
PBMCs from 18 different patients with GPA in cohort II
were thawed and co-cultured with 51Cr-labeled K562
target cells. The cytotoxic response after 4 hours of co-
culture was not detectable in the majority of PBMCs
from patients with active GPA (n = 7) (Fig. 6a, left
graph), whereas the PBMCs from HC and from the ma-
jority of patients in remission (n = 11) responded typic-
ally to K562 targets (Fig. 6a, right graph). For further
comments on single patients, see the legend of Fig. 6b.
On statistical analysis of the highest effector (viable
PBMC)/target ratio, PBMCs from active GPA had sig-
nificantly reduced natural cytotoxicity (Fig. 6c). Differ-
ences in NK cell percentages within the PBMCs (shown
in Fig. 2) could account for this effect. Additionally, NK
cell activity per se could be altered in patients with ac-
tive GPA. We therefore calculated the number of NK
cells within the PBMCs for each sample. In both HC
and patients with GPA, there was good correlation be-
tween the percentage of lysed target cells and the calcu-
lated NK/target ratio (Fig. 6d). A linear regression model
of the relationship between target cell lysis and the NK/
target ratio revealed that more GPA NK cells would be
needed to obtain the same target cell lysis as HC NK
cells (Fig. 6d): to reach a 50 % target cell lysis, an NK/
target ratio of 1.8 was statistically sufficient in HC, but a
ratio of 3.1 was needed in patients with GPA.
NK cell cytotoxicity in relation to immunosuppressive
treatment
There was no correlation between prednisone dosage
and cytotoxicity (Additional file 4: Figure S2B). We com-
pared the cytotoxicity after subgrouping according to
immunosuppressive drugs (Additional file 4: Figure S2F).
Similar to what was observed in the expression of CD16
and CD69 on CD56dim (CD16 pos.) NK cells, on statis-
tical analysis using the Kruskal-Wallis test there was no
statistic difference between the patient groups. The
Kruskal-Wallis test was only positive after the inclusion
of the HC; the only positive post hoc test was again the
comparison between HC and the six patients who re-
ceived azathioprine (four of whom were not in remis-
sion). Comparing patients receiving azathioprine and
rituximab according to GPA activity, we observed a clear
tendency towards alterations in cytotoxicity that were
more prominent in patients in the non-remission group
(Additional file 4: Figure S2F).
In summary, the natural cytotoxicity of active PBMCs
was reduced to incommensurability, which can be traced
back to low NK cell numbers. In addition, we observed
decreased cytotoxicity on the re-calculated per-cell level.
Discussion
Despite their important function in immune defense and
regulation, the role of NK cells in many autoimmune or
inflammatory diseases remains unexplored. Only re-
cently have the first publications on NK cells in GPA
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Fig. 5 Increased expression of adhesion molecule CD54 (ICAM-1), chemokine receptor CCR5 and NKG2C on CD56dim natural killer (NK) cells in
active (non-remission) granulomatosis with polyangiitis (GPA). Experimental setting, patients and analysis as described in Fig. 3, using multicolor
panel III. a Left mean fluorescent intensity (MFI) of CD54 on CD56dim NK cells; Kruskal-Wallis test, p = 0.0108; middle percentage of CCR5-positive
CD56dim NK cells (Kruskal-Wallis test, p = 0.0204); right percentage of CXCR3-positive CD56dim NK cells (Kruskal-Wallis test not significant). b Left
percentage of NKG2C on CD56dim NK cells (Kruskal-Wallis test, p = 0.0227); right percentage of NKG2C on CD56bright NK cells (Kruskall-Wallis test
not significant). a, b Dunn's post hoc test was significant where indicated in the graphs. HC healthy controls
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emerged [15, 21]. Importantly, in our previous study
peripheral blood NK cell percentages in long-term re-
mission were significantly higher than in active GPA and
control groups [15]. These clinical correlations war-
ranted further investigation.
In the first part of this study, we addressed this issue
by adding a second cohort of patients, providing both
absolute and relative lymphocyte subset counts. We con-
firmed normal NK cells percentages in active GPA and
high NK cell percentages in long-term remission, despite
increased patient numbers and slightly altered analysis
methods. Next, we reported, for the first time, lower ab-
solute NK cell counts in non-remission vs. remission
GPA. It is important to note that while overall B cell and
T cell lymphopenia persist during active and inactive
GPA, the absolute NK cell counts were significantly
higher in remission.
In addition, the majority of patients with non-remission
GPA had NK cell counts lower than the clinically
established normal threshold, indicating a true decrease in
NK cells in non-remission GPA. This true decrease was not
formally confirmed when comparing non-remission GPA
with inactive CD, as the corresponding post hoc test was
not significant. However, the direct comparison of non-
remission GPA and CD using the Mann-Whitney test was
significant. This borderline significance is presumably due
to the relatively low number of patients with CD and the
large range of scattered NK counts within the CD group.
The follow up during induction therapy suggests an
intra-individual increase in NK cells over time. In line with
this, we observed a tendency towards a decrease in NK
cell percentages during flaring disease activity among pa-
tients who were investigated at different time points in
both cohorts. Together, these data sustain the inverse cor-
relation between NK cells and the disease course.
In the second part of this study, we systematically ana-
lyzed NK cell subsets and their phenotype. The CD56dim
subset was identified as the reduced and altered NK cell
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Fig. 6 Natural cytotoxicity is not measurable in active (non-remission) granulomatosis with polyangiitis (GPA). Freshly isolated, thawed peripheral
blood mononuclear cells (PBMCs) from 11 healthy controls (HC) and patients with GPA from cohort II (in remission = 11 and non-remission = 7
patients; total = 18) were cultured overnight in medium. After washing PBMCs (effector cells) and 51Cr-labeled K562 (target) cells were co-cultured
for 4 hours without further stimulation. The highest effector (PBMC)/target (E:T) ratio was 25:1, only viable PBMCs were counted. Percent specific
lysis was determined by measuring 51Cr in the supernatant. The sensitivity threshold of this assay lies at about 5–10 % specific lysis. a No natural
cytotoxicity was detectable in PBMCs from 7/18 patients (left), whereas typical cytotoxicity curves were measured in PBMCs from the remaining
11/18 patients and all HC (right). b Analysis of the GPA activity states in patients revealed that PBMCs without natural cytotoxic response were all
from patients in the non-remission group, except for the two patients with the lowest natural killer (NK)/target ratios within the remission group
(0.96 and 1.1, respectively). Two patients from the non-remission group exhibited measurable minor natural cytotoxicity; both were clinically
categorized as having "grumbling disease". c Statistical analysis at the highest E (viable PBMC):T ratio (25:1); Kruskal-Wallis test, p = 0.0016; Dunn's
post hoc test was significant where indicated in the graph. d NK/target ratios of the highest E:T were calculated based on the percentages of NK
cells in PBMCs and blotted against the percentage of lysed target cells (% specific lysis); linear equation, r2, Spearman's r and statistical significance
of the correlation as indicated in the graphs
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fraction in active GPA. There were no significant differ-
ences on further subtyping of CD56dim NK cells accord-
ing to the maturity markers CD62L and CD57. CD56dim
NK cells are characterized by the expression of the Fc-
receptor CD16. Importantly, CD16bright cells were
strongly reduced in active GPA. This alteration is prom-
inent, given the importance of the receptor [11]. In
addition, CD16 polymorphisms have been identified as a
risk factor in GPA [22]. CD56dim(CD16 pos.) NK cells
also showed signs of acute (CD69 and CD54) and
chronic (NKG2C) activation, and de novo expression of
CCR5 in active GPA. The normal expression patterns of
the majority of the investigated NK cell receptors
(Additional file 3: Figure S1) confirms the specificity of
these phenotypic changes. Upon cytomegalovirus (CMV)
reactivation, NKG2C-positive NK cells increase; however,
only two patients in our patient cohort had documented
CMV reactivation within recent years.
Alternative to the disease and/or its activity, pheno-
typic changes may be due to medication. The dissection
of treatment and/or disease-mediated alterations ob-
served in ex vivo biomaterial is a known challenge (con-
founder by treatment vs. confounder by indication/
disease activity). Based on our treatment analysis
(Additional file 4: Figure S2), we conclude that a con-
founder by treatment in the sense of a general effect of
immunosuppression cannot be completely excluded, but
effects were not drug-specific. Disease activity seems to
be a major confounder of the only statistically significant
post hoc test that could be detected between treatment
groups, i.e. patients taking azathioprine vs. HC. In
addition to that, the tendency of more pronounced alter-
ations in patients with active vs. inactive GPA who re-
ceived the same drugs clearly indicates that disease
activity is closely related to the phenotypic and func-
tional alterations observed in this study.
Together, these findings suggest the involvement of
NK cells in active GPA. In this context, two possible ex-
planations for decreased NK cell counts could exist,
namely different migration and activation-induced NK
cell death:
1) The elevation of the adhesion molecule CD54 and
the chemokine receptor CCR5 might be indicative
of a difference in migration. It is unclear, into which
tissues NK cells would migrate, as we did not detect
NK cells in granulomas [15]. Alternatively, NK cells
could die in granulomas, or migrate into secondary
lymphoid tissues
2) The activated phenotype and the downregulation of
CD16 could be a sign of Fc-induced activation of NK
cells (Merkt et al. 2016, unpublished observations)
[14], e.g. by cell-bound autoantibodies. Alternatively,
CD16 downregulation could be secondary to induced
matrix metalloproteinases [12, 13]. GPA is a classic
autoimmune disease characterized by the existence of
autoantibodies, and chronic stimulation by cell-bound
autoantibodies could lead to activation-induced cell
death and thus, reduced NK cell numbers
These considerations could be combined into an inte-
grative model: CD16 of peripheral blood CD56dim NK
cells could recognize proteinase3-autoantibodies bound
on endothelial cells, which activates them and increases
the expression of CD54 (and presumably CCR5). As a
result, they might transmigrate through the blood vessel
wall, sustaining endothelial damage, and die due to
activation-induced cell death. After induction therapy,
autoantibodies and activating chemokines may decrease
[23], resulting in reduced NK cell migration and death,
leading to increased counts in peripheral blood.
This model gives no explanation why NK cell percent-
ages further increase during long-term remission. In-
creased NK cell proportions might include changes in
NK cell maturation, development, proliferation or sur-
vival. Based on the existing literature, elevated blood
levels of IL-15 and IL-18 [23], a disturbed control by T
regulatory cells [24] and different migration due to
changes of chemotactic receptors (Fig. 5 and [25]) also
need to be considered. Based on mouse models, it had
been suggested that lymphopenia itself could also be a
stimulus for NK cell proliferation [8]. Elevated propor-
tions in remission and decreased counts in active GPA
are likely to be the result of two distinct mechanisms,
because phenotypic alterations were more prominent in
active GPA. Accordingly, NK cells might have different
roles in remission and active GPA.
In the last part of this study, we described overall defi-
ciency of natural cytotoxicity towards the classic NK cell
target K562 in active GPA. The killing of K562 is inde-
pendent of CD16 and depends on NKG2D, the ligand of
which has been detected in the tissues in GPA [26, 27],
and on inflammatory endothelial cells [28]. Therefore,
the reduced natural cytotoxicity towards K562 might be
relevant in GPA. Based on the correlation between lysed
K562 cells and NK cell counts, the reduced NK cell
numbers in active GPA are responsible for the dysfunc-
tional overall natural killing. However, we also observed
a reduced killing capacity at the re-calculated per-cell
level in GPA in general, indicating that a second mech-
anism could lead to reduced natural cytotoxicity. How-
ever, the latter finding needs validation using isolated
NK cells, which could not be done in the present study
because of a limited amount of available PBMCs.
While several studies [29] report decreased NK cell
numbers and impaired cytotoxicity in other autoimmune
diseases, there is a lack of studies in GPA. Systemic
lupus erythematosus (SLE) is such another disease.
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Hervier et al. [30] describe numerical, phenotypic and
functional alterations in NK cells in SLE that are at least
in part similar to those reported here in GPA, including
downregulated CD16 and upregulated CD69 and
NKG2C. Therefore, some of our findings could be a gen-
eral feature of active autoantibody-mediated systemic in-
flammatory diseases. These similarities are encouraging,
as they might reflect (measurable) disease activity, and
comparisons might open new strategies for common or
specific treatment targets. In any case, increased NK cell
percentages in remission above HC levels have, to the
best of our knowledge, not been described in other dis-
eases and appear to be characteristic of GPA [15].
Together, the alterations in active GPA implicate a role
in GPA pathogenesis. In the long run, NK cell numbers
and their phenotype (CD16, CD69, NKG2C) or natural
cytotoxicity are promising candidates to serve as clinical
biomarkers to determine GPA activity. In addition, the
described phenotypic changes might help to form a basis
for new therapeutic strategies in GPA.
Conclusions
In summary, we provided further evidence of correlation
between blood NK cells and clinical suppression of dis-
ease activity. We described for the first time that re-
duced numbers of CD56dim NK cells in active GPA
exhibit an activated and altered phenotype and are asso-
ciated with deficient overall natural cytotoxicity.
Additional files
Additional file 1: Antibody/staining panels. (DOCX 13 kb)
Additional file 2: Figure S3. Age was not different between HC, CD
and patients with active or inactive (non-remission) GPA in NK cell
phenotype analysis. Shown are patients and HC as presented in Figs. 3, 4
and 5 and patients with CD as shown in Fig. 2. Bars indicate medians.
The Kruskal-Wallis test revealed no significant differences between the
groups. Y-axes show age in years. (PDF 5 kb)
Additional file 3: Figure S1. The expression of numerous NK cell
receptors is not different in HC and patients with GPA in remission or
with active GPA. The percentage of the indicated receptors on CD56dim
NK cells is shown for healthy controls (HC) and GPA in remission (ir) and
non-remission (nr). Statistical analysis using the Kruskal-Wallis test revealed
no significant differences. The percentage of NKG2D-positive NK cells is
underestimated due to weak fluorescence intensity of the FITC-labeled
antibody; the example of a histogram shows that almost all CD56dim NK
cells express NKG2D. (PDF 112 kb)
Additional file 4: Figure S2 NK cell phenotype and cytotoxicity in
relation to immunosuppressive treatment. Patients and methods as
indicated in Fig. 4. a, b Prednisone dosages. a Prednisone dosages were
not significantly (ns) different between patients in remission and in non-
remission. b There was no correlation between prednisone dosage and
the proportion of CD16bright and CD69 pos. CD56dimCD16 pos. NK cells
(for experimental details see Fig. 3) or cytotoxicity (% specific lysis, for
experimental details see Fig. 6). c-f Other immunosuppressive drugs. c CYC
cyclophosphamide, RTX rituximab (rituximab was given 7.3 (remission) and
8.3 (non-remission) months (means) prior to inclusion in the study), AZA
azathioprine, MTX methotrexate, LEF leflunomide (AZA, MTX and LEF were
introduced >/= 5 months prior to the inclusion in the study; the starting point
of LEF from a could not be retrieved for one patient), double IS combination
therapies, no IS no immunosuppressive drugs apart from prednisone. Of note,
AZA was more often taken by patients in non-remission, whereas MTX, LEF
and MPA were more often taken by patients in remission. d-f Left graphs show
the frequencies of CD16bright CD56dimCD16 pos. NK cells, CD69 pos.
CD56dimCD16 pos. NK cells and cytotoxicity (% specific lysis) after subgrouping
according to immunosuppressive drugs apart from prednisone, respectively.
Statistical analysis using the Kruskal-Wallis test revealed that there was no
statistical difference between patient groups. Upon inclusion of HC, the
Kruskal-Wallis test was positive; the only positive post hoc tests were HC vs.
patients who received azathioprine. For two treatment groups (rituximab and
azathioprine) patients in remission (black dots) were opposed to those in
non-remission (red dots). The remaining treatment groups were not depicted
as only each one patient or no patient at all were in non-remission. Bars
represent medians. (PDF 109 kb)
Additional file 5: Figure S4. CD54, CCR5 and NKG2C were not
increased on the same CD56dim NK cells. Experimental setting, patients
and analysis as described in Fig. 5. The mean MFI of CD54 on CD56dim
NK cells and the percentages of CCR5-positive and CXCR3-positive
CD56dim NK cells depending on the co-expression of NKG2C are shown.
The same donors are linked by lines. The Wilcoxon signed rank test was
significant where indicated in the graph; *p = 0.0156. (PDF 169 kb)
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